Grant opportunityOpen
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
PAR-25-226 · NIH
Grant details are part of the paid plan
Award amounts, eligibility, deadlines, and the application link — plus grant alerts the moment new funding posts.
Create an account →